Reinventing the discovery, development, and commercialization of new medicines

Roivant named to Fast Company's Best Workplaces for Innovators List

See the full list here

Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old

Read the full press release here

Collecting Pharma’s Scraps Can Pay Off for This Biotech

Wall Street Journal

One person’s trash can be another’s treasure. That is essentially the idea behind Roivant ROIV -4.92%decrease; red down pointing triangle, a biotech company with a handful of drugs it got from pharma’s dustbin.

Roivant was founded by the controversial billionaire Vivek Ramaswamy on the premise that large biotech and pharma companies are often too big and complex, creating an opportunity for companies that can focus on a single therapy. The company, which creates a subsidiary “vant” for each new drug it gets, has had both failures and successes, including a notable late-stage flop in Alzheimer’s as well as the $3 billion sale of five of its companies to Japan’s Sumitomo Pharma.

Matt Gline wants you to stop thinking of Roivant as a discard company. In 2023, he'll prove it

FierceBiotech

Matt Gline has had enough of the quips. Over the course of his seven-year tenure at Roivant Sciences—the last two as CEO—he's fended off what he thinks are condescending characterizations that the “vant” parent company is a discard-reliant pharma and prognostications about the potential of the drugs it works on.